Satsuma Pharmaceuticals Analysis
What is Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals develops innovative therapeutics for acute migraine treatment, focusing on STS101, a dihydroergotamine nasal powder.
Founded
2016
Business Model
Research and development of therapeutics; revenue from commercialization and partnerships.
Company Stage
Other
YC Batch
S21
Product Features & Capabilities
- STS101, Dihydroergotamine (DHE) Nasal Powder, Acute treatment of migraine with or without aura, Investigational product, Not yet FDA approved.
Who are the founders of Satsuma Pharmaceuticals
Market Focus
Satsuma Pharmaceuticals primarily focuses on the pharmaceutical industry, specifically in developing innovative therapeutics for the acute treatment of migraines.
Investors
- TPG
- Vivo Capital
- CAM Capital
- Citadel Enterprise Americas
- Commodore Capital
- Cormorant Asset Management
- 16 other unnamed investors
Competitors Overview
Satsuma Pharmaceuticals operates in the migraine treatment market, focusing on innovative therapeutics, particularly their lead product candidate, STS101, a dihydroergotamine nasal powder. The main competitors in this market include:
- Biohaven Pharmaceuticals: Known for its product, Nurtec OD
See something that needs updating? Suggest edits to this profile.